Valuation : Lundbeck

Market Cap 43.73B 6.78B 5.85B 5.51B 5.02B 9.39B 641B 9.46B 65.27B 25.33B 328B 25.47B 24.92B 1,076B P/E 2026 *
9.73x
P/E 2027 * 9.56x
Enterprise Value 47.73B 7.4B 6.39B 6.02B 5.48B 10.25B 699B 10.32B 71.24B 27.65B 358B 27.8B 27.2B 1,175B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.67x
Free-Float
30.74%
Yield 2026 *
3.51%
Yield 2027 * 3.16%
1 day+2.58%
1 week+3.43%
Current month+4.55%
1 month+21.39%
3 months+20.05%
6 months+25.57%
Current year+20.72%
1 week 40.85
Extreme 40.85
44.65
1 month 35.1
Extreme 35.1
44.65
Current year 31.4
Extreme 31.4
44.65
1 year 31.4
Extreme 31.4
44.65
3 years 23.3
Extreme 23.3
44.65
5 years 21.94
Extreme 21.935
44.65
10 years 21.94
Extreme 21.935
44.65
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2023
Director of Finance/CFO 49 01/09/2022
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 25/03/2015
Director/Board Member 67 25/03/2015
Director/Board Member 60 20/03/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.58%+3.43% - - 6.62B
+1.99%+3.14%+33.71%+124.28% 106B
+2.57%+2.97%+64.15%+180.30% 55.67B
+0.56%-4.93%-12.62%+241.77% 22.3B
-0.24%-0.12%-11.57%-8.35% 8.16B
-0.91%-0.55%-40.31%-28.89% 7.14B
+2.46%+3.61%+9.67%+25.62% 6.62B
+0.42%+0.12%-2.97%+20.07% 5.1B
+2.29%+16.32%+297.41%+471.96% 4.35B
+1.44%+1.18%+11.58%+15.96% 3.75B
Average +1.30%+1.37%+38.79%+115.86% 24.31B
Weighted average by Cap. +1.79%+1.40%+35.91%+140.20%

Financials

2026 *2027 *
Net sales 25.92B 4.02B 3.47B 3.27B 2.98B 5.56B 380B 5.61B 38.68B 15.01B 194B 15.1B 14.77B 638B 26.05B 4.04B 3.49B 3.28B 2.99B 5.59B 382B 5.64B 38.89B 15.09B 195B 15.18B 14.84B 641B
Net income 4.59B 711M 614M 578M 527M 985M 67.21B 992M 6.84B 2.66B 34.36B 2.67B 2.61B 113B 4.65B 721M 622M 586M 534M 998M 68.12B 1.01B 6.94B 2.69B 34.83B 2.71B 2.65B 114B
Net Debt 4B 621M 536M 505M 460M 859M 58.66B 866M 5.97B 2.32B 29.99B 2.33B 2.28B 98.52B -178M -27.57M -23.78M -22.4M -20.41M -38.15M -2.6B -38.44M -265M -103M -1.33B -104M -101M -4.37B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
02/09/26 DKK 43.70 +2.58% 243,235
01/09/26 DKK 42.60 +1.91% 251,082
31/08/26 DKK 41.80 +1.83% 140,977
28/08/26 DKK 41.05 -0.61% 99,823
27/08/26 DKK 41.30 -0.12% 153,935
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
44.22DKK
Average target price
48.73DKK
Spread / Average Target
+10.20%

Quarterly revenue - Rate of surprise